NCT03383978View on ClinicalTrials.gov

Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Glioblastoma
Interventions
BIOLOGICAL

NK-92/5.28.z

Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8

DRUG

Ezabenlimab

Intravenous infusion of Ezabenlimab 240mg q 3 weeks

Trial Locations (4)

55131

Neurochirurgische Klinik, Universitätsmedizin Mainz, Mainz

60528

Johann W. Goethe University Hospital, Department of Neurosurgery, Frankfurt

Johann W. Goethe University Hospital, Senckenberg Institute of Neurooncology, Frankfurt

68167

Neurochirurgische Klinik, Universitätsmedizin Mannheim, Mannheim

All Listed Sponsors
collaborator

DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH

UNKNOWN

collaborator

Georg-Speyer-Haus

UNKNOWN

collaborator

LOEWE Center Frankfurt Cancer Institute

UNKNOWN

collaborator

German Cancer Research Center

OTHER

lead

Johann Wolfgang Goethe University Hospital

OTHER